Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio. But executives argue its “compelling and highly differentiated value” ...

Morgan Stanley analyst Michael Ulz assumed coverage of Rhythm Pharmaceuticals (RYTM) with an Overweight rating and $72 price target The firm expects positive Phase 3 setmelanotide data in ...

Investors in Rhythm Pharmaceuticals Inc (Symbol: RYTM) saw new options begin trading today, for the May 16th expiration. One of the key inputs that goes into the price an option buyer is willing ...

Shares of RYTM opened at $53.22 on Monday. Rhythm Pharmaceuticals has a 52 week low of $35.17 and a 52 week high of $68.58. The firm has a market cap of $3.27 billion, a price-to-earnings ratio of ...

DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix ...

The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million during the quarter, compared to analyst estimates ...

After-Hours Stock Movers: Rhythm Pharmaceuticals (NASDAQ:RYTM) 14% LOWER; Confirmed the FDA has approved the Company’s supplemental New Drug Application (sNDA) for IMCIVREE®... Stifel Nicolaus ...

The image below shows how its cash balance has been changing over the last few years. At first glance it's a bit worrying to see that Rhythm Pharmaceuticals actually boosted its cash burn by 16% ...